Overview

BR1010 in Patients With Essential Hypertension Patients Who do Not Adequately Respond to Fimasartan/Amlodipine Combination

Status:
Completed
Trial end date:
2021-03-02
Target enrollment:
Participant gender:
Summary
The objective of this clinical study is to evaluate the efficacy and safety by comparing the BR1010 treatment group to the fimasartan/amlodipine treatment group at Week 8 in patients with essential hypertension who do not adequately respond to Fimasartan/Amlodipine combination
Phase:
Phase 3
Details
Lead Sponsor:
Boryung Pharmaceutical Co., Ltd
Treatments:
Amlodipine